论文部分内容阅读
目的观察甲状腺内注射地塞米松磷酸钠(DSP)联合口服左旋甲状腺素钠(LT4)治疗伴亚临床甲减的桥本甲状腺炎(HT)的治疗效果。方法选择医院2015年2月-2016年9月收治的伴亚临床甲减的HT患者58例,随机分为研究组和对照组各29例,对照组给予LT4治疗,研究组在对照组基础上给予DSP治疗,比较2组患者治疗前后血清甲状腺过氧化物酶抗体(TPOAb)、甲状腺球蛋白抗体(TGAb)、游离三碘甲状腺原氨酸(FT_3)、游离甲状腺素(FT_4)及促甲状腺激素(STSH)水平。结果治疗前2组TPOAb、TGAb、FT_3、FT_4、STSH比较差异均无统计学意义(P>0.05),2组患者治疗后血清TPOAb、TGAb、FT_3、FT_4、STSH水平均显著改善,且研究组优于对照组,差异均有统计学意义(P<0.05)。结论 DSP联合LT4治疗伴亚临床甲减的HT疗效显著,能有效降低患者血清TPOAb、TGAb、FT_3、FT_4及STSH水平,帮助患者恢复健康。
Objective To observe the therapeutic effect of intrathyroidal injection of dexamethasone sodium phosphate (DSP) combined with oral levothyroxine sodium (LT4) on Hashimoto’s thyroiditis (HT) with subclinical hypothyroidism. Methods Fifty-eight HT patients with sub-clinical hypothyroidism admitted from February 2015 to September 2016 in our hospital were randomly divided into study group (29 cases) and control group (n = 29), and control group received LT4 treatment. The study group was divided into control group The serum levels of TPOAb, TGAb, FT_3, FT_4 and thyroid stimulating hormone (TSH) were measured before and after treatment with DSP. (STSH) level. Results There was no significant difference in TPOAb, TGAb, FT_3, FT_4 and STSH between the two groups before treatment (P> 0.05). The levels of serum TPOAb, TGAb, FT_3, FT_4 and STSH in two groups were significantly improved after treatment The difference was statistically significant (P <0.05). Conclusion The combination therapy of DSP and LT4 with subclinical hypothyroidism can significantly reduce the levels of serum TPOAb, TGAb, FT_3, FT_4 and STSH in patients and help the patients recover their health.